Integra Lifesciences Holdings (IART) Total Non-Current Liabilities (2009 - 2026)

Integra Lifesciences Holdings has disclosed Total Non-Current Liabilities across 18 years of filings, most recently posting $2.3 billion for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities fell 2.12% year-over-year to $2.3 billion; the TTM figure through Jun 2026 stood at $2.3 billion (down 2.12% YoY), while the FY2025 annual figure was $2.4 billion, changed 0.36% from the prior year.
• Total Non-Current Liabilities came in at $2.3 billion for Q2 2026 at Integra Lifesciences Holdings, down from $2.3 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $2.4 billion in Q2 2024 to a low of $1.9 billion in Q1 2023.
• Average Total Non-Current Liabilities over 5 years is $2.2 billion, with a median of $2.3 billion recorded in 2026.
• Year-over-year, Total Non-Current Liabilities retreated 4.66% in 2022 and rose 22.89% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $1.9 billion in 2022, then grew by 2.43% to $2.0 billion in 2023, then increased by 17.64% to $2.3 billion in 2024, then climbed by 0.36% to $2.4 billion in 2025, then slipped by 1.21% to $2.3 billion in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $2.3 billion in Q2 2026, $2.3 billion in Q1 2026, and $2.4 billion in Q4 2025.